Nanocrystals of medium soluble actives-Novel concept for improved dermal delivery and production strategy

被引:65
作者
Zhai, Xuezhen [1 ]
Lademann, Juergen [2 ]
Keck, Cornelia M. [1 ,3 ]
Mueller, Rainer H. [1 ]
机构
[1] Free Univ Berlin, Dept Pharmaceut Biopharmaceut & NutriCosmet, Inst Pharm, D-12169 Berlin, Germany
[2] Charite, Charite Campus Mitte, Ctr Expt & Appl Cutaneous Physiol CCP, Dept Dermatol Venerol & Allergol, D-10117 Berlin, Germany
[3] Univ Appl Sci Kaiserslautern, Fachhsch, D-66953 Pirmasens, Germany
关键词
Nanocrystals; High pressure homogenization; Pearl milling; Dermal application; Hair follicle accumulation; Penetration enhancement; DRUG-DELIVERY; PENETRATION; WATER; TECHNOLOGY; SOLUBILITY; CAFFEINE; ETHANOL; SKIN;
D O I
10.1016/j.ijpharm.2014.04.060
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
After use in oral pharmaceutical products, nanocrystals are meanwhile applied to improve the dermal penetration of cosmetic actives (e.g. rutin, hesperidin) and of drugs. By now, nanocrystals are only dermally applied made from poorly soluble actives. The novel concept is to formulate nanocrystals also from medium soluble actives, and to apply a dermal formulation containing additionally nanocrystals. The nanocrystals should act as fast dissolving depot, increase saturation solubility and especially accumulate in the hair follicles, to further increase skin penetration. Caffeine was used as model compound with relevance to market products, and a particular process was developed for the production of caffeine nanocrystals to overcome the supersaturation related effect of crystal growth and fiber formation - typical with medium soluble compounds. It is based on low energy milling (pearl milling) in combination with low dielectric constant dispersion media (water-ethanol or ethanol-propylene glycol mixtures) and optimal stabilizers. Most successful was Carbopol (R) 981 (e.g. 20% caffeine in ethanol-propylene glycol 3:7 with 2% Carbopol, w/w). Nanocrystals with varied sizes can now be produced in a controlled process e.g. 660 nm (optimal for hair follicle accumulation) to 250 nm (optimal for fast dissolution). The short term test proved stability over 2 months of the present formulation being sufficient to perform in vivo testing of the novel concept. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:141 / 150
页数:10
相关论文
共 33 条
[1]  
Anger S., 2005, THESIS FREIE U BERLI
[2]   New aspects of the skin barrier organization [J].
Bouwstra, J ;
Pilgram, G ;
Gooris, G ;
Koerten, H ;
Ponec, M .
SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY, 2001, 14 :52-62
[3]   Role of polymeric stabilizers for drug nanocrystal dispersions [J].
Choi, JY ;
Yoo, JY ;
Kwak, HS ;
Nam, BU ;
Lee, J .
CURRENT APPLIED PHYSICS, 2005, 5 (05) :472-474
[4]   SURFACTANTS AND EXPERIMENTAL IRRITANT CONTACT-DERMATITIS [J].
EFFENDY, I ;
MAIBACH, HI .
CONTACT DERMATITIS, 1995, 33 (04) :217-225
[5]   Safety Assessment of Propylene Glycol, Tripropylene Glycol, and PPGs as Used in Cosmetics [J].
Fiume, Monice M. ;
Bergfeld, Wilma F. ;
Belsito, Donald V. ;
Hill, Ronald A. ;
Klaassen, Curtis D. ;
Liebler, Daniel ;
Marks, James G., Jr. ;
Shank, Ronald C. ;
Slaga, Thomas J. ;
Snyder, Paul W. ;
Andersen, F. Alan .
INTERNATIONAL JOURNAL OF TOXICOLOGY, 2012, 31 :245S-260S
[6]  
Fratus M., 2011, THESIS FREIE U BERLI
[7]   Modulation of the barrier function of the skin [J].
Hadgraft, J .
SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY, 2001, 14 :72-81
[8]   Nanocrystal technology, drug delivery and clinical applications [J].
Junghanns, Jens-Uwe A. H. ;
Mueller, Rainer H. .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2008, 3 (03) :295-309
[9]   Long-term stability of quercetin nanocrystals prepared by different methods [J].
Kakran, Mitali ;
Shegokar, Ranjita ;
Sahoo, Nanda Gopal ;
Gohla, Sven ;
Li, Lin ;
Mueller, Rainer H. .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 64 (10) :1394-1402
[10]   Fabrication of quercetin nanocrystals: Comparison of different methods [J].
Kakran, Mitali ;
Shegokar, Ranjita ;
Sahoo, Nanda Gopal ;
Al Shaal, Loaye ;
Li, Lin ;
Mueller, Rainer H. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 80 (01) :113-121